Skip main navigation

Molecular Mechanisms Involved in the Angiotensin-(1-7)/Mas Signaling Pathway in Cardiomyocytes

Originally published 2008;52:542–548


Recently there has been growing evidence suggesting that beneficial effects of angiotensin-(1-7) [Ang-(1-7)] in the heart are mediated by its receptor Mas. However, the signaling pathways involved in these effects in cardiomyocytes are unknown. Here, we investigated the involvement of the Ang-(1-7)/Mas axis in NO generation and Ca2+ handling in adult ventricular myocytes using a combination of molecular biology, intracellular Ca2+ imaging, and confocal microscopy. Acute Ang-(1-7) treatment (10 nmol/L) leads to NO production and activates endothelial NO synthase and Akt in cardiomyocytes. Ang-(1-7)–dependent NO raise was abolished by pretreatment with A-779 (1 μmol/L). To confirm that Ang-(1-7) action is mediated by Mas, we used cardiomyocytes isolated from Mas-deficient mice. In Mas-deficient cardiomyocytes, Ang-(1-7) failed to increase NO levels. Moreover, Mas-ablation was accompanied by significant alterations in the proteins involved in the regulation of endothelial NO synthase activity, indicating that endothelial NO synthase and its binding partners are important effectors of the Mas-mediated pathway in cardiomyocytes. We then investigated the role of the Ang-(1-7)/Mas axis on Ca2+ signaling. Cardiomyocytes treated with 10 nmol/L of Ang-(1-7) did not show changes in Ca2+-transient parameters such as peak Ca2+ transients and kinetics of decay. Nevertheless, cardiomyocytes from Mas-deficient mice presented reduced peak and slower [Ca2+]i transients when compared with wild-type cardiomyocytes. Lower Ca2+ ATPase of the sarcoplasmic reticulum expression levels accompanied the reduced Ca2+ transient in Mas-deficient cardiomyocytes. Therefore, chronic Mas-deficiency leads to impaired Ca2+ handling in cardiomyocytes. Collectively, these observations reveal a key role for the Ang-(1-7)/Mas axis as a modulator of cardiomyocyte function.

The renin-angiotensin system plays a major role in the pathogenesis of cardiovascular diseases.1 Although angiotensin (Ang) II is the major effector of this system, several other peptides are now recognized as being biologically important. Of particular importance is the heptapeptide Ang-(1-7). Accordingly, Ang-(1-7) has been reported to have a pivotal role in the regulation of the cardiovascular system.2,3 Briefly, this peptide decreased the incidence and duration of ischemia-reperfusion arrhythmias,4 improved the postischemic contractile function in isolated perfused rat hearts, and prevented Ang II–induced cardiac remodeling.5 Previously, we have reported that Ang-(1-7) is an endogenous ligand for the G protein–coupled receptor Mas.6 In keeping with this finding, many of the cardiovascular effects of Ang-(1-7) can be completely blocked by the selective Mas antagonist A-779,7 suggesting an important role for the Ang-(1-7)/Mas axis in the cardiovascular system. Supporting these findings, Mas-deficient (Mas−/−) mice present reduced cardiac function characterized by decreased fractional shortening.8 Overall, these studies indicate that interactions between Ang-(1-7) and Mas play an important role in cardiac function, and genetic deletion of Mas leads to cardiac impairment and endothelial dysfunction.9 However, the cellular mechanism and signaling pathways involved in Ang-(1-7)/Mas actions in the cardiac cell are not defined. Recently, Sampaio et al10 have demonstrated that Ang-(1-7) actions in endothelial cells cause endothelial NO synthase (eNOS) phosphorylation and result in NO release through the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt)–dependent pathway. Ang-(1-7) via Mas also reduce the overall growth of cardiomyocytes.11 In this study, we investigated the involvement of the Ang-(1-7)/Mas axis in NO generation and Ca2+ handling in adult ventricular myocytes.


For expanded Methods please see the data supplement available online at


Twenty-five wild-type (WT) and 22 Mas knockout (Mas−/−) on FVB/N genetic background male mice (3 to 6 months old) were obtained from the transgenic animal facilities of the Federal University of Minas Gerais Laboratory of Hypertension. All of the experimental protocols conform to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by our institution.

Cardiomyocyte Isolation and Confocal Imaging

Freshly isolated ventricular myocytes were stored in DMEM (Sigma Aldrich) until they were used12 (within 4 hours). Confocal images were obtained using the ZEISS Meta confocal microscope (Zeiss Germany) from CEMEL (Biological Sciences Institute, Federal University of Minas Gerais).


Ang-(1-7) Increases NO Production in Ventricular Cardiomyocytes

To investigate whether Ang-(1-7) is able to generate NO in adult ventricular myocytes, we used the fluorescent indicator 4-amino-5methylamino-2′,7′-difluorofluorescein (DAF-FM) to monitor cellular NO generation. Cells were exposed to Ang-(1-7) for 15 minutes, and maximal DAF fluorescence was observed at 10 nmol/L (Figure 1A), showing a concentration-dependent increase on NO generation by Ang-(1-7) in cardiomyocytes. Figure 1B shows that Ang-(1-7)–dependent (10 nmol/L; 15 minutes) NO raise is abolished by the NO synthase inhibitor NG-nitro-l-arginine methyl ester (10 μmol/L; 15 minutes). On the other hand, the inactive isomer NG-nitro-d-arginine methyl ester had no effect on Ang-(1-7)–induced NO raise, indicating that Ang-(1-7) stimulates NO generation in cardiomyocytes. To further confirm the specificity of the DAF probe, we incubated cardiomyocytes with the NO donor sodium nitroprusside (Figure S1). Ang-(1-7)–induced NO generation presented a time dependence, as shown in Figure 1C, and significant NO generation occurred 5 minutes after Ang-(1-7) stimulation. LY294002, a PI3K inhibitor (10 μmol/L), blocked the Ang-(1-7)–induced increase in NO fluorescence in cardiomyocytes, suggesting the involvement of the PI3K/Akt pathway in Ang-(1-7) effects in cardiomyocytes (Figure 1D). To confirm whether Ang-(1-7) stimulation in cardiomyocytes leads to Akt activation, we examined the time course of Akt phosphorylation in Ang-(1-7)–treated cells. As shown in Figure 1E, Akt phosphorylation induced by Ang-(1-7) increased significantly in a time-dependent manner. Both endothelial NO synthase (eNOS) and neuronal NO synthase participate in NO production in the heart. The fact that Ang-(1-7) via Akt mediates eNOS activation in endothelial cells prompted us to investigate whether Ang-(1-7) stimulation also results in eNOS activation in cardiomyocytes. eNOS activity is regulated through coordinated phosphorylation of specific sites. Phosphorylation of eNOS at Ser 1177 (stimulatory site) results in an increase in enzyme activity and NO production, whereas eNOS phosphorylation at Thr 495 (inhibitory site) reduces enzyme activity and NO production. As shown in Figure 1F, Ang-(1-7) induced eNOS Ser1177 phosphorylation in a time-dependent manner similar to the effects of Ang-(1-7) on Akt activation and NO generation. To verify whether Ang-(1-7) actions on ventricular myocytes occurred via Mas, cells were preincubated with the Mas antagonist A-779 (1 μmol/L; 15 minutes) and then stimulated with Ang-(1-7) (10 nmol/L; 15 minutes). Figure 2A and 2B show that A-779 prevented the Ang-(1-7)–dependent increase in NO. Moreover, the changes in eNOS and Akt phosphorylation levels by Ang-(1-7) were also blocked by A-779 treatment (Figure 2C through 2E).

Figure 1. Ang-(1-7) signaling pathway involved in NO generation in cardiomyocytes. A, Concentration-dependent effect of Ang-(1-7) on NO generation in ventricular cardiomyocytes. Each bar represents data from ≥35 cells. B, Averaged-bar graph represents NO generation in adult ventricular myocytes after acute Ang-(1-7) treatment (10 nmol/L; 15 minutes). In NG-nitro-l-arginine methyl ester–pretreated cells, Ang-(1-7)–dependent NO raise was abolished. C, Time course of NO generation after acute Ang-(1-7) treatment. D, Pretreatment of cardiomyocytes with PI3K inhibitor (LY294002) prevented Ang-(1-7)–stimulated NO raise. In A through D, n=number of cardiomyocytes. E and F, Representative Western blot (top) and bar graph show the time-dependent increase in Akt and eNOS phosphorylation levels after Ang-(1-7) stimulation of cardiomyocytes (bottom). n indicates the number of cardiomyocyte homogenates. GAPDH expression levels were used as a loading control. #P<0.05 vs control; *P<0.05. In B and D, †P<0.05 vs Ang-(1-7)–treated cells.

Figure 2. Ang-(1-7) stimulates NO release in cardiomyocytes through Mas. A, Representative confocal images showing DAF-loaded cardiomyocytes from WT mice untreated (control, left), mice treated with Ang-(1-7) (middle), or mice treated with with Ang-(1-7) and the Mas antagonist A-779 (right). Bar=10 μm. B, Averaged DAF fluorescence increase in adult ventricular myocytes after acute Ang-(1-7) treatment (10 nmol/L) for 15 minutes. Application of Mas antagonist A-779 (1 μmol/L) inhibited the increase in DAF fluorescence in Ang-(1-7)–treated cardiomyocytes. n indicates the number of cells. C and D, Top, Representative blots showing Ang-(1-7)–dependent increase in eNOS Ser1177 and concomitant decrease in eNOS Thr 495 phosphorylation levels in WT cardiomyocytes. Preincubation with A-779 prevented Ang-(1-7)–dependent effects in eNOS phosphorylation. Bottom, Averaged bar graph shows the significant increase (C) or decrease (D) in eNOS phosphorylation site levels in Ang-(1-7)—treated cardiomyocytes compared with control and A-779–treated cells. E, Top, Representative blots. Bottom, Averaged bar graph shows the relative increase in Akt phosphorylation by Ang-(1-7). A significant increase in Akt phosphorylation level was observed after Ang-(1-7) treatment. C through E, GAPDH expression levels were used as a loading control. n=number of cardiomyocyte homogenates. #P<0.05 vs control; *P<0.05.

Ang-(1-7)–Induced NO Generation Is Abolished in Mas−/− Cardiomyocytes

To further investigate the role of Mas in Ang-(1-7)–dependent NO generation in cardiac cells, we used cardiomyocytes isolated from Mas−/− mice. Figure 3 shows that NO fluorescence failed to augment in Mas−/− cardiomyocytes treated with Ang-(1-7) (10 nmol/L; 15 minutes), supporting our findings presented in Figure 2. As expected, the Mas antagonist A-779 had no effect on DAF fluorescence in Ang-(1-7)–treated Mas−/− cardiomyocytes. Taken together, Figures 1 to 3 show strong evidence for a role of the Ang-(1-7)/Mas axis in the NO generation of adult ventricular myocytes and reveal a previously unknown signaling pathway in cardiac cells.

Figure 3. Ang-(1-7) failed to raise NO levels in Mas−/− cardiomyocytes. A, Representative confocal images showing DAF-loaded Mas−/− cardiomyocytes untreated (control, left), treated with Ang-(1-7) (middle), or treated with Ang-(1-7) and the Mas antagonist A-779 (right). Bar=10 μm. B, Averaged DAF fluorescence in Mas−/− cardiomyocytes was unaltered by Ang-(1-7) treatment. n indicates the number of cells.

Mas Ablation Is Accompanied by Changes in Proteins Involved in the Regulation of eNOS Activity

In cardiomyocytes, eNOS is part of a macromolecular complex composed of caveolin-3, heat shock protein 90 (Hsp90), and Akt. Caveolin-3 has been shown to directly interact with eNOS and inhibits its basal activity by preventing calmodulin interaction.13 Hsp90 acts as a scaffold protein to recruit Akt in the eNOS complex, thereby promoting eNOS phosphorylation–dependent activation.14 The third component, Akt, phosphorylates eNOS at Ser 1177, rendering the enzyme active.13 To investigate possible alterations in the proteins involved in the regulation of eNOS in Mas−/− cardiomyocytes, we performed Western blot analyses in protein homogenates from isolated cardiomyocytes. Immunoblots revealed similar eNOS protein levels in cardiomyocytes from Mas−/− mice when compared with control cells (Figure 4A). In contrast, Western blot analysis showed augmented expression of caveolin-3 (by 77%; Figure 4B) in Mas−/− cardiomyocytes. We also observed a significant reduction in levels of Hsp90 in Mas−/− cardiomyocytes when compared with control cells (Figure 4C). We next evaluated Akt and Akt phosphorylation levels in these cells. Increased Akt levels were observed in Mas−/− cardiomyocytes (by ≈56%; Figure 4D). This result was further confirmed by immunofluorescence techniques where cardiomyocytes from Mas−/− and WT mice were stained with specific antibodies against Akt. Confocal images in Figure 4E show increased Akt levels in Mas−/− cardiomyocytes. To verify Akt activation in Mas−/− cardiomyocytes, we assessed phosphorylated Akt levels in these cells. Although Akt expression was higher in Mas−/− cells, phosphorylated Akt levels were significantly reduced, suggesting that less active enzyme was found in Mas−/− cells when compared with control cardiomyocytes (Figure 4F). These data clearly show changes in expression levels of proteins involving the eNOS complex in Mas−/− cardiomyocytes.

Figure 4. Molecular alterations in proteins involved in eNOS activity regulation in Mas−/− cardiomyocytes. Expression of eNOS and its binding partners in adult ventricular myocyte homogenates were assessed by immunoblot techniques with specific antibodies. A, eNOS protein levels were unaltered in cardiomyocytes from Mas−/− mice. B, Caveolin-3 expression levels were higher in Mas−/− cardiomyocytes when compared with WT cells. In contrast, reduced Hsp90 expression was observed in Mas−/− cardiomyocytes (C). D, Akt protein levels were significantly higher in Mas−/− cardiomyocytes, whereas phosphorylated Akt levels were lower in these cells (F). E, Immunofluorescence using an anti-Akt–specific antibody showed increased Akt expression (green) in Mas−/− cardiomyocytes. The nucleus is stained with 4′,6-diamidino-2-phenylindole (blue). Bar=10 μm. A through F, Top, Representative Western blots; bottom, averaged densitometry. GAPDH expression levels were used as a loading control. #P<0.05. n indicates the number of cardiomyocyte homogenates.

Increased Apoptosis in the Mas−/− Heart

Recently, evidence was presented that NO plays an important role in apoptotic cell death.15,16 There is evidence suggesting that high concentrations of NO produced from inducible NO synthase induce apoptosis, whereas low concentrations of NO produced from eNOS reduce apoptosis.15 Given the potential protective effect triggered by eNOS activation in cardiac cells,14 we hypothesized that Mas−/− hearts could exhibit a higher apoptosis rate, because these hearts present significant alterations in proteins involved in eNOS regulation. To investigate this issue, Mas−/− hearts were stained using a TUNEL assay, and the total fluorescence was quantified. Figure S2 shows that prominent apoptosis was evident in the left and right ventricles of Mas−/− mice when compared with WT hearts. Mean fluorescence levels were significantly higher in the ventricle of Mas−/− mice when compared with WT mice, suggesting that differences in apoptotic cell death contribute significantly to Mas−/− cardiac defects.

Ca2+ Signaling Defects in Mas−/− Cardiomyocytes

To investigate the role of the Ang-(1-7)/Mas axis on cardiomyocyte Ca2+ dynamics, isolated cardiomyocytes were loaded with the Ca2+ sensitive dye Fluo-4/AM, treated with Ang-(1-7) and visualized by confocal microscopy. Top panels of Figure S3A display representative line-scanning images recorded from electrically stimulated (at 1 Hz) cardiomyocytes treated or not with 10 nmol/L of Ang-(1-7) for 15 minutes. Figure S3B shows that acute Ang-(1-7) treatment failed to increase peak Ca2+ transient in WT cardiomyocytes. In a similar way, Ang-(1-7) treatment did not alter Ca2+ transient kinetics of decay (Figure S3C). Nevertheless, Mas−/− cardiomyocytes showed a significantly smaller peak [Ca2+]i transient (F/F0=3.54±0.08, n=147, in WT versus F/F0=3.059±0.60, n=147, in Mas−/− cardiomyocytes; Figure 5A and 5B), and slower [Ca2+]i transient kinetics of decay when compared with WT cardiomyocytes (Figure 5C and 5D). These results were consistent with the depression of contractility that has been observed previously in Mas−/− hearts.8 We also treated Mas−/− cardiomyocytes with Ang-(1-7). Peak Ca2+ transient and kinetics of decay in Mas−/− cardiomyocytes were not altered by Ang-(1-7) treatment (data not shown). In cardiomyocytes, Ca2+ ATPases found on the sarcoplasmic reticulum (SERCA2a) permit rapid reuptake of the Ca2+ released from the sarcoplasmic reticulum. Therefore, we hypothesized that the slow decline of the [Ca2+]i transient in Mas−/− myocytes may be caused by alterations in SERCA2a activity or expression levels. SERCA2a expression levels were then assessed by immunoblot in WT and Mas−/− cardiomyocytes. A significant reduction in SERCA2a (by 53%) was found in cardiomyocytes from Mas−/− mice relative to WT cardiomyocytes (Figure 5E). Reduced SERCA2a levels in Mas−/− cardiomyocytes can explain, at least in part, the changes in Ca2+ handling observed in these cells.

Figure 5. Ca2+ signaling defects in Mas−/− cardiomyocytes. A, Sample line-scan image (top) and Ca2+ transient profile (bottom) from WT and Mas−/− cardiomyocytes. B, Bar graph shows averaged-peak Ca2+ transient from electrically stimulated cardiomyocytes (1 Hz). Mas−/− cardiomyocytes presented significantly reduced Ca2+ transients than WT cardiomyocytes. C and D, Averaged Ca2+-transient kinetics of decay. Mas−/− cardiomyocytes presented slower Ca2+-transient kinetics of decay than WT cardiomyocytes. T50 and T90 represent the time from peak Ca2+ transient to 50% and 90% decay, respectively. n indicates the number of cardiomyocytes. E, Significantly reduced SERCA2a levels were observed in Mas−/− cardiomyocytes when compared with WT cells. GAPDH expression was used as a loading control. n indicates the number of cardiomyocyte homogenates. #P<0.05.


Recently, multiple lines of evidence have shown that the beneficial effects of Ang-(1-7) in the heart are mediated by Mas. However, the signaling pathways involved in these effects on ventricular myocytes are unknown. In this study, we have made several novel observations. First, we demonstrated that Ang-(1-7) via Mas increased NO production and provided direct evidence that eNOS and PI3K/Akt are downstream mediators of Ang-(1-7) signaling pathway in cardiomyocytes. We further confirmed these data by showing that Mas−/− cardiomyocytes lacked Ang-(1-7)–induced NO production. Second, we have characterized alterations in expression levels of proteins involved in regulation of eNOS activity in Mas−/− cardiomyocytes, revealing an important link between Mas and the eNOS macromolecular complex in cardiac cells. Third, we have characterized a Ca2+ signaling dysfunction in Mas−/− cardiomyocytes, suggesting an important role for Mas in the long-term maintenance of normal Ca2+ handling in the cell. We have also shown that acute Ang-(1-7) treatment failed to alter Ca2+ handling in ventricular myocytes excluding a direct alteration of Ca2+ handling protein function by Ang-(1-7) in our experimental condition. To our knowledge, this work is the first demonstration of the signaling pathways involved in Ang-(1-7)/Mas effects in ventricular myocytes.

Ang-(1-7)/Mas Signaling Pathways in Adult Ventricular Cardiomyocytes

Sampaio et al10 have demonstrated that Ang-(1-7) actions in endothelial cells cause eNOS phosphorylation, resulting in NO release through the PI3K/Akt-dependent pathway. Here, we have shown direct evidence that eNOS and PI3K/Akt are downstream effectors in the Ang-(1-7) signaling pathway in ventricular myocytes. Multiple lines of investigation suggest that activation of the PI3K/Akt pathway is a critical determinant of cell survival and growth in a variety of signaling pathways.17 Given the beneficial effects of Ang-(1-7) in the heart, it seems likely that activation of this pathway plays an important role in Ang-(1-7) cardioprotective effects.

Our data are in agreement with a recent observation by Giani et al18 showing that Ang-(1-7) via Mas stimulates the phosphorylation of Akt in the heart; however, this previous study was performed using whole heart homogenates. By using isolated ventricular myocytes, we specifically addressed the downstream mediators involved in the Ang-(1-7) signaling pathway in the cardiac cell. Nevertheless, a variety of regulators have been identified that influence NO synthesis by regulation of eNOS phosphorylation, including kinases and phosphatases.14

The lack of a significant effect of Ang-(1-7) on Ca2+ handling in cardiomyocytes does not exclude the possibility that Ang-(1-7) might indirectly affect Ca2+ handling protein function. It is well established that constitutive NO production modulates the function of various components of cardiomyocyte excitation-contraction coupling.19 Martinez-Moreno et al20 have shown that a fraction of the total eNOS protein directly associates with RyR2. In keeping with this finding, Petroff et al21 suggested that eNOS-derived NO enhanced RyR2 open probability in cardiomyocytes in response to stretch. Moreover, there has been some evidence in the literature supporting an interplay among eNOS, cGMP-dependent protein kinase, and Ca2+ handling in cardiomyocytes.22 Accordingly, insulin treatment of cardiomyocytes increased phosphorylation and activity of eNOS, leading to augmented phospholamban phosphorylation and consequent SERCA2a activation in reoxygenated cardiomyocytes. In this context, Ang-(1-7)–dependent NO could modulate the activity of multiple Ca2+ handling proteins in the cell. On the other hand, it is possible that alterations in the proteins involving the eNOS complex and consequent reduction in eNOS activity in Mas−/− cardiomyocytes contribute to the Ca2+ handling dysfunction observed in these cells and might be related to SERCA2a changes. This finding is particularly important because it shows for the first time that the Ang-(1-7)/Mas axis is important for long-term maintenance of normal Ca2+ handling in the cardiac cell. Nevertheless, we cannot exclude the possibility that a decreased level of SERCA2a is secondary to the cardiac dysfunction observed in Mas−/− hearts. Additional experiments are necessary to elucidate the relationship between the Ang-(1-7)–dependent NO signaling pathway and Ca2+ handling in cardiomyocytes.

eNOS-Derived NO in Cardiomyocytes

Both eNOS and neuronal NO synthase participate in NO production in the heart. In this work, we showed direct evidence of eNOS as a downstream factor in the Ang-(1-7) signaling pathway in cardiomyocytes. Moreover, we showed that Ang-(1-7) increased NO production in cardiac cells in a time-dependent manner through the PI3K/Akt-dependent pathway. Although we cannot exclude a role of neuronal NO synthase in NO production in adult cardiomyocytes, we believe that, at least in part, we can attribute NO generated by Ang-(1-7) in adult cardiomyocytes to eNOS. Two sets of data support this finding: Ang-(1-7) treatment of cardiomyocytes leads to eNOS activation, and Mas-ablation leads to alterations in proteins involved in eNOS regulation in the cell. Although we did not observe changes in eNOS expression levels between Mas−/− and WT cardiomyocytes, we believe that eNOS activity in these cells is reduced (see below). Interestingly, Ang II type 2 receptor–deficient mice showed decreased cardiac eNOS expression.23 The contribution of neuronal NO synthase to NO generation in control and Mas−/− cardiomyocytes awaits elucidation.

Reduced eNOS Activity in Mas−/− Cardiomyocytes

Several factors support the finding that eNOS activity is reduced in Mas−/− cardiomyocytes, the first being increased caveolin-3 expression and consequent eNOS inhibition. Garcia-Cardena et al24 have shown that peptides corresponding to the scaffolding domain of caveolin-3 inhibit eNOS in cardiomyocytes. In keeping with this finding NO synthase activity is reduced in caveolin-3–overexpressing hearts.25 Second, Mas−/− cardiomyocytes show reduced Hsp90 levels. Low levels of Hsp90 reduce Akt recruitment to the eNOS complex, thereby preventing eNOS-dependent Akt activation. Third, Mas−/− cardiomyocytes present reduced Akt activity because of reduced phospho-Akt levels in these cells. Together, these data reveal an important association between receptor Mas and the eNOS signaling complex in adult cardiomyocytes.

There is evidence in the literature suggesting a cardioprotective role of eNOS-derived NO.26 Specifically, regulation of NO synthesis in the heart by eNOS represents a critical final common pathway to explain the benefit of several effective treatments for both acute myocardial ischemia and chronic congestive cardiac failure.14 Thus, it is possible that the alterations in the proteins involving the eNOS complex and consequent reduction in eNOS activity contribute to the cardiac dysfunction in Mas−/− hearts, including the increased apoptosis rate. However, it should be noted that, in addition to the potential cardioprotective effect triggered by eNOS, previous studies also indicated a deleterious effect of eNOS-derived NO during myocardial ischemia/reperfusion.27


Ang-(1-7) has been reported to have a pivotal role in the regulation of the cardiovascular system. We now report that Ang-(1-7) via Mas activates the PI3K/Akt pathway and eNOS, leading to NO production in cardiomyocytes. These data suggest that eNOS and Akt are important downstream effectors of the Ang-(1-7)/Mas-mediated pathway in cardiomyocytes and possibly play important roles in Ang-(1-7) beneficial effects in the heart. Our data reveal a previously unknown signaling pathway involved in NO production dependent on the Ang-(1-7)/Mas axis in ventricular myocytes that plays an important role in the regulation of cardiomyocyte function. During the development of pathological conditions, dysregulation of the Ang-(1-7) signaling pathway may contribute to the ventricular dysfunction observed under these conditions.

Sources of Funding

This work was supported by grants from Deutscher Akademischer Austauschdienst (PROBRAL program of DAAD/CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; S.G. and R.A.S.S.), Fundação de Amparo à Pesquisa do Estado de Minas Gerais (S.G.), Instituto Milênio (S.G.), PRPq/UFMG (S.G.), and PRONEX. M.N.M.A. is recipient of CNPq PhD fellowship. M.F.D.-P. and E.R.M.G. are recipients of a CAPES Fellowship. L.G. has a PIBIC/CNPq Fellowship.




Correspondence to Silvia Guatimosim, Institute of Biological Sciences, Federal University of Minas Gerais, Av Antônio Carlos 6627, Belo Horizonte, MG-CEP 31270-901, Brazil. E-mail


  • 1 Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med. 2003; 13: 93–101.CrossrefMedlineGoogle Scholar
  • 2 Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005; 289: H2281–H2290.CrossrefMedlineGoogle Scholar
  • 3 Santos RA, Frezard F, Ferreira AJ. Angiotensin-(1-7): blood, heart, and blood vessels. Curr Med Chem Cardiovasc Hematol Agents. 2005; 3: 383–391.CrossrefMedlineGoogle Scholar
  • 4 Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension. 2001; 38: 665–668.CrossrefMedlineGoogle Scholar
  • 5 Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007; 292: H736–H742.CrossrefMedlineGoogle Scholar
  • 6 Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003; 100: 8258–8263.CrossrefMedlineGoogle Scholar
  • 7 Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept. 2000; 91: 45–62.CrossrefMedlineGoogle Scholar
  • 8 Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension. 2006; 47: 996–1002.LinkGoogle Scholar
  • 9 Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V, Alenina N, Santos RA. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension. 2008; 51: 574–580.LinkGoogle Scholar
  • 10 Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007; 49: 185–192.LinkGoogle Scholar
  • 11 Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol. 2005; 289: H1560–H1566.CrossrefMedlineGoogle Scholar
  • 12 Guatimosim S, Sobie EA, dos Santos CJ, Martin LA, Lederer WJ. Molecular identification of a TTX-sensitive Ca(2+) current. Am J Physiol Cell Physiol. 2001; 280: C1327–C1339.CrossrefMedlineGoogle Scholar
  • 13 Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann N Y Acad Sci. 2002; 962: 122–130.CrossrefMedlineGoogle Scholar
  • 14 Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol. 2007; 42: 271–279.CrossrefMedlineGoogle Scholar
  • 15 Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther. 2005; 106: 147–162.CrossrefMedlineGoogle Scholar
  • 16 Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, Ma XL. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 2002; 105: 1497–1502.LinkGoogle Scholar
  • 17 Matsui T, Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol. 2005; 38: 63–71.CrossrefMedlineGoogle Scholar
  • 18 Giani JF, Gironacci MM, Munoz MC, Pena C, Turyn D, Dominici FP. Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am J Physiol Heart Circ Physiol. 2007; 293: H1154–H1163.CrossrefMedlineGoogle Scholar
  • 19 Hare JM. Nitric oxide and excitation-contraction coupling. J Mol Cell Cardiol. 2003; 35: 719–729.CrossrefMedlineGoogle Scholar
  • 20 Martinez-Moreno M, varez-Barrientos A, Roncal F, Albar JP, Gavilanes F, Lamas S, Rodriguez-Crespo I. Direct interaction between the reductase domain of endothelial nitric oxide synthase and the ryanodine receptor. FEBS Lett. 2005; 579: 3159–3163.CrossrefMedlineGoogle Scholar
  • 21 Petroff MG, Kim SH, Pepe S, Dessy C, Marban E, Balligand JL, Sollott SJ. Endogenous nitric oxide mechanisms mediate the stretch dependence of Ca2+ release in cardiomyocytes. Nat Cell Biol. 2001; 3: 867–873.CrossrefMedlineGoogle Scholar
  • 22 Abdallah Y, Gkatzoflia A, Gligorievski D, Kasseckert S, Euler G, Schluter KD, Schafer M, Piper HM, Schafer C. Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage. Cardiovasc Res. 2006; 70: 346–353.CrossrefMedlineGoogle Scholar
  • 23 Brede M, Roell W, Ritter O, Wiesmann F, Jahns R, Haase A, Fleischmann BK, Hein L. Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Hypertension. 2003; 42: 1177–1182.LinkGoogle Scholar
  • 24 Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, Sessa WC. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J Biol Chem. 1997; 272: 25437–25440.CrossrefMedlineGoogle Scholar
  • 25 Aravamudan B, Volonte D, Ramani R, Gursoy E, Lisanti MP, London B, Galbiati F. Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype. Hum Mol Genet. 2003; 12: 2777–2788.CrossrefMedlineGoogle Scholar
  • 26 Massion PB, Balligand JL. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice. J Physiol. 2003; 546: 63–75.CrossrefMedlineGoogle Scholar
  • 27 Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol. 2001; 33: 1897–1918.CrossrefMedlineGoogle Scholar


eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.